The global AI in drug-discovery market, valued at approximately $3.25 billion in 2026, is projected to reach more than $10 billion by 2031, according to industry reports. Oncotelic Therapeutics (OTCQB: OTLC), a California-based oncology company, is positioning itself at the center of this shift with its proprietary PDAOAI platform. The company recently announced the successful integration of approximately 28 million scientific abstracts into the platform, a milestone that underscores its ambition to become more than just a drug-discovery tool.
Artificial intelligence is rapidly becoming the defining infrastructure layer of modern drug development. The companies that control the most intelligent platforms may ultimately control the industry’s future. Oncotelic’s central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs. By aggregating and analyzing vast amounts of scientific data, the platform aims to identify novel drug targets, predict drug efficacy, and reduce the time and cost of bringing new therapies to market.
The integration of 28 million scientific abstracts represents a significant leap in the platform's capabilities. This vast dataset allows the AI to draw connections between disparate research findings, potentially unlocking insights that would be impossible for human researchers to uncover. For a clinical-stage company with limited resources relative to big pharma, this approach levels the playing field and demonstrates that small biotechs can out-innovate larger competitors.
Oncotelic’s strategy is particularly noteworthy in the context of the broader market. The AI in drug-discovery market is growing at a compound annual growth rate of roughly 26% through 2031, highlighting the increasing reliance on AI to streamline drug development. Oncotelic’s focus on oncology positions it in a high-demand therapeutic area where AI can have a transformative impact on identifying effective treatments.
The company’s progress is being closely watched by investors and industry analysts. For more information about Oncotelic and its latest developments, visit the company’s newsroom at ibn.fm/OTLC. This article is based on a press release distributed by InvestorWire, a communications platform for private and public companies. InvestorWire is part of the Dynamic Brand Portfolio @IBN and offers services including wire-grade press release syndication, article syndication to 5,000+ outlets, and social media distribution. For full terms and disclaimers, visit the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
